Key result
This review summarizes key 2014 cardiovascular evidence, including antiplatelet therapy, colchicine for pericarditis, atrial fibrillation guidelines, and novel heart failure and hyperlipidemia drugs.
This review highlights practice-changing cardiovascular evidence from 2014 across multiple subspecialties for internal medicine physicians.
Answers are grounded in this paper and cite their sources.
Synthesizes 2014 CV evidence for clinicians; leaves open need for updated reviews in evolving fields.
Updates5 May 2015Update in Cardiology: Evidence Published in 2014Daniel A. Steinhaus, MD and Peter J. Zimetbaum, MDDaniel A. Steinhaus, MDFrom Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.Search for more papers by this author and Peter J. Zimetbaum, MDFrom Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-0272 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This update summarizes key articles in cardiovascular disease published in 2014. We selected these articles for their novelty, potential effects on clinical practice, and general interest for physicians in internal medicine practice. New studies of antiplatelet therapy helped guide both primary and secondary prevention of coronary artery disease. Ongoing research has established the benefits of colchicine in the treatment of recurrent pericarditis. New guidelines for the management of atrial fibrillation were also practice-changing. Novel medical therapies are anticipated for heart failure (neprilysin inhibition) and hyperlipidemia (anti–proprotein convertase subtilisin/kexin type 9). However, new therapies for heart failure with preserved systolic function ... Author, Article, and Disclosure InformationAffiliations: From Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0272.Corresponding Author: Peter Zimetbaum, MD, Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Baker 4, Boston, MA 02215; e-mail, [email protected]harvard.edu.Current Author Addresses: Drs. Steinhaus and Zimetbaum: Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Baker 4, Boston, MA 02215.Author Contributions: Conception and design: D.A. Steinhaus, P.J. Zimetbaum.Analysis and interpretation of the data: D.A. Steinhaus.Drafting of the article: D.A. Steinhaus, P.J. Zimetbaum.Critical revision of the article for important intellectual content: D.A. Steinhaus, P.J. Zimetbaum.Final approval of the article: D.A. Steinhaus, P.J. Zimetbaum.Collection and assembly of data: D.A. Steinhaus.This article was published online first at www.annals.org on 30 April 2015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 May 2015Volume 162, Issue 9Page: W86-W90KeywordsAntiplatelet therapyAtrial fibrillationColchicineEjection fractionHeart failureMyocardial infarction ePublished: 5 May 2015 Issue Published: 5 May 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Steinhaus et al. (2015) conducted a review in Cardiovascular disease. This review summarizes key 2014 cardiovascular evidence, including antiplatelet therapy, colchicine for pericarditis, atrial fibrillation guidelines, and novel heart failure and hyperlipidemia drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: